Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 382 | 78 | 300 |
| Samples | 341 | 74 | 265 |
| Peptides | 240 | 50 | 199 |
Function
PLA2G3 · Phospholipase A2 group III
This gene encodes a protein that belongs to the secreted phospholipase A2 family, whose members include the bee venom enzyme. The encoded enzyme functions in lipid metabolism and catalyzes the calcium-dependent hydrolysis of the sn-2 acyl bond of phospholipids to release arachidonic acid and lysophospholipids. This enzyme acts as a negative regulator of ciliogenesis, and may play a role in cancer development by stimulating tumor cell growth and angiogenesis. This gene is associated with oxidative stress, and polymorphisms in this gene are linked to risk for Alzheimer's disease. [provided by RefSeq, Apr 2014].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000215885 | Q9NZ20 | 382 | 240 |
Gene Properties
Recurrent Mutations
All 240 amino-acid changes on canonical ENST00000215885 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PLA2G3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PLA2G3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Endometrial Carcinoma | 4/42 10% | 20/612 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Melanoma | 6/210 3% | 50/1899 3% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Colorectal Carcinoma | 14/143 10% | 35/3239 1% |
| Gastric Carcinoma | 5/74 7% | 21/1809 1% |
| Cervical Carcinoma | 3/35 9% | 3/422 1% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 12/1390 1% |
| Ovarian Carcinoma | 4/109 4% | 7/998 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 15/1592 1% |
| Bladder Carcinoma | 1/58 2% | 8/956 1% |
| Other Solid Cancers | 0/94 0% | 13/1515 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 5/810 1% |
| Pancreatic Carcinoma | 2/89 2% | 8/1611 0% |
| Hepatocellular Carcinoma | 0/46 0% | 13/2210 1% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Neuroendocrine Tumour | 1/154 1% | 2/577 0% |
| Other Sarcomas | 1/69 1% | 2/699 0% |
| Head and Neck Carcinoma | 3/85 4% | 3/1574 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Neuroblastoma | 2/87 2% | 2/1331 0% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 3/2534 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Prostate Carcinoma | 2/13 15% | 3/2105 0% |
| Other Blood Cancers | 1/61 2% | 5/2725 0% |
Mutation Distribution
Where PLA2G3 is mutated · all tissues, split by cell line vs tissue
How many mutations in PLA2G3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 48 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 382 mutations in PLA2G3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|